NIH Funding Sustains Scientific Discovery
The Duke Department of Pharmacology and Cancer Biology ranks seventh in the nation in NIH funding, based on grants awarded during the federal fiscal year ending September 30, 2024.
Explainer: Why Universities Need Support for Research Facilities and Administrative Costs
The National Institutes of Health's proposal to cap reimbursement of facilities and administrative (F&A) costs on research grants at 15% would significantly slow or cease scientific and biomedical research at Duke and other research institutions. Here is an explanation of what F&A costs are and why they are such a critical piece of the research endeavor.
Three Questions with: Trudy G. Oliver
Dr. Oliver is focused on understanding the biology of under-studied subtypes of lung cancer, specifically squamous and small cell lung cancer. Her lab investigates mechanisms of tumor development, plasticity, and drug resistance to uncover vulnerabilities that can be therapeutically targeted.
Tsvetanova Receives ASPET Division for Molecular Pharmacology Early Career Award
Nikoleta Tsvetanova, PhD, assistant professor of pharmacology and cancer biology, has been awarded the 2025 Division for Molecular Pharmacology Early Career Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET).
McDonnell Wins Endocrine Society’s Baxter Prize for Entrepreneurship
Donald McDonnell, PhD, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, has been awarded the Endocrine Society’s J
Wang Promoted to Full Professor
G. Greg Wang is among five faculty in the School of Medicine who have been promoted or appointed to the rank of full professor.
PhD candidate Min-Yu Ko receives 2024 PhRMA Foundation Predoctoral Fellowship in Drug Discovery
Ko was awarded the fellowship for his research studying how low levels of androgens facilitate activation of a specific protein, resulting in increased tumor growth. He hopes to develop drugs that exploit this protein signaling process to inhibit prostate cancer cell growth.
Lee Zou To Serve as a Fellow in the 2025 ACC Academic Leaders Network Program
Zou is one of several fellows from Duke who will participate in a year of joint institutional activities designed to build awareness and effectiveness in the context of academic leadership. The provosts of the Atlantic Coast Conference member institutions created the Academic Leaders Network Program to develop the leadership potential of participating faculty.
Tavros Therapeutics Acquired by Subsidiary of Bayer AG
Tavros Therapeutics, co-founded by Kris Wood, PhD, associate professor of pharmacology and cancer biology, and Eoin McDonnell, PhD, a graduate of the Duke University Molecular Cancer Biology PhD Program , has been acquired by Vividion Therapeutics, a subsidiary of global life sciences company Bayer AG.